Cubala, WJ, Bajbouj, M, Bauer, M, Baune, BT, Cardoner, N, Devlin, F, Doolin, K, Herrero, RMD, Elices, M, Feeney, A, Galuszko-Wegielnik, M, Jakuszkowiak-Wojten, K, Janu, L, Kelly, JR, Ledden, K, Maclsaac, R, Madero, S, Mcinerney, SJ, Montejo, AL, Nawka, A, Pálenícek, T, Solà, VP, Ramaekers, JG, Reif, A, Ritter, P, Ryan, F, Svendsen, CB, Sweeney, C, Terwey, TH, Trivedi, MH, Valcheva, V, Vieta, E, Thase, ME. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026; 83(6)DOI:10.1001/jamapsychiatry.2026.0096. PMID:41879760. IF:17.100(Q1/1D).

Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of three strategies of GvHD prophylaxis after T-cell replete haploidentical hematopoietic transplantation: Tacrolimus vs calcineurin inhibitors-MMF vs sirolimus-MMF (vol 30, pg 1025, 2024). Transplantation And Cellular Therapy. 2026; 32(6)DOI:10.1016/j.jtct.2025.06.011. PMID:40516920. IF:4.400(Q1/1D).

Fox, ML, Martínez, AP, Esquirol, A, Navarro, V, Cabirta, A, García-Cadenas, I, Almorox, RB, Fonseca-Santos, M, Fernando, IH, Bento, L, Raya, MP, Montoro, J, Calbacho, M, Ripa, TZ, Coll, CFI, Morales, RH, Ortí, G, Martino, R, González, PFC, López-Corral, L, Pérez-López, E, Navarro-Fernandez, J, Cascón, MJP, Sola, M, Catarineu, AT, Salamero, O, González, AP, Solano, C, Kwon, M, Valcárcel, D. Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC. Transplantation And Cellular Therapy. 2026; 32(6)DOI:10.1016/j.jtct.2026.01.013. PMID:41534839. IF:4.400(Q1/1D).

Esquirol, A, Pascual, MJ, Garcia-Cadenas, I, Herruzo, B, Ferra, C, Torio, A, Torrent, A, Cuesta, M, Martino, R, Sierra, J. Combining three different pre-transplant scores improves predictive value in patients after haploidentical stem cell transplantation with TBF conditioning and PTCy (vol 27 , pg 614.e1 , 2021 ). Transplantation And Cellular Therapy. 2026; 32(6)DOI:10.1016/j.jtct.2025.06.010. PMID:40623446. IF:4.400(Q1/1D).

Powles, T, van der Heijden, MS, Bedke, J, Valderrama, BP, Kikuchi, E, Galsky, MD, Loriot, Y, Iyer, G, Yu, EY, Hoffman-Censits, J, Mar, N, Vulsteke, C, Sridhar, SS, Maroto-Rey, JP, Park, SH, Moreno, BH, Lichfield, J, Yu, XS, Wirtz, H, Gupta, S. Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.4507. PMID:. IF:41.900(Q1/1D).

Portu, M, Sanz-Beltran, J, Pellicer, A, Navarro, B, Monleon, AR, Capdevila, P, Tallafigo, FL, Moran, T, Catot, S, Munoz, SP, Arriola, E, Sanchez, A, Osorio, K, Muñoz, A, Isla, D, Guarner, B, Piedra, A, Recio, SM, Barba, A, Majem, M. Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8107. PMID:. IF:41.900(Q1/1D).